TECH · Full Picture

BIO-TECHNE Corp — the full picture

Trailing window · 2026-05-12 to 2026-08-10

One earnings window, everything merged: the filing, the call, press releases and news digests, folded into ranked threads.

What to look at first

  1. Acquisition / Partnership / Divestiture · M&A and divestituresPriority 56
    1 forward row(s); quote_verified
    Amundi reduced its stake in Bio-Techne Corp (NASDAQ:TECH) by 67.2% during the first quarter, selling 148,342 shares and retaining 72,315 shares valued at approximately $3.8 million.
  2. Revenue Performance and Mix · Revenue growth & mixPriority 25
    quote_verified
    Bio-Techne's revenue was down 1.5% year-over-year to $311.42 million in Q1.
  3. Market Demand Trends · Demand, orders & backlogPriority 22
    quote_verified
    Bio-Techne is benefiting from subsiding temporary headwinds, including improving academic funding and strong large pharmaceutical customer demand.

Threads by pillar

Revenue & Demand Priority 27 · 2 threads

Strategy & Portfolio Priority 56 · 1 thread